FUT7

Summary

FUT7 (fucosyltransferase 7, HGNC:4018) is a protein-coding gene on chromosome 9q34.3, encoding Alpha-(1,3)-fucosyltransferase 7 (Q11130). Catalyzes the transfer of L-fucose, from a guanosine diphosphate-beta-L-fucose, to the N-acetyl glucosamine (GlcNAc) of a distal alpha2,3 sialylated lactosamine unit of a glycoprotein or a glycolipid-linked sialopolylactosamines chain through an alpha-1,3 glycosidic linkage and….

The protein encoded by this gene is a Golgi stack membrane protein that is involved in the creation of sialyl-Lewis X antigens. The encoded protein can direct the synthesis of the E-selectin-binding sialyl-Lewis X moiety.

Source: NCBI Gene 2529 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 64 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_004479

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4018
Approved symbol	FUT7
Name	fucosyltransferase 7
Location	9q34.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000180549
Ensembl biotype	protein_coding
OMIM	602030
Entrez	2529

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000314412, ENST00000874316

RefSeq mRNA: 1 — MANE Select: NM_004479 NM_004479

CCDS: CCDS7022

Canonical transcript exons

ENST00000314412 — 2 exons

Exon	Start	End
ENSE00001252647	137030174	137031725
ENSE00001410261	137031979	137032088

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 97.06.

FANTOM5 (CAGE): breadth broad, TPM avg 1.2704 / max 115.0156, expressed in 187 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
103286	0.6249	122
103289	0.1751	74
103287	0.1500	64
103290	0.1461	49
103288	0.1158	60
103285	0.0584	29

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
olfactory bulb	UBERON:0002264	97.06	gold quality
type B pancreatic cell	CL:0000169	96.11	gold quality
vena cava	UBERON:0004087	95.96	gold quality
tongue squamous epithelium	UBERON:0006919	93.94	gold quality
body of tongue	UBERON:0011876	93.28	gold quality
cardia of stomach	UBERON:0001162	92.84	gold quality
parotid gland	UBERON:0001831	92.81	gold quality
lateral nuclear group of thalamus	UBERON:0002736	92.50	gold quality
triceps brachii	UBERON:0001509	92.32	gold quality
subthalamic nucleus	UBERON:0001906	92.00	gold quality
pericardium	UBERON:0002407	91.98	gold quality
tongue	UBERON:0001723	91.61	gold quality
substantia nigra pars reticulata	UBERON:0001966	91.53	gold quality
pylorus	UBERON:0001166	91.49	gold quality
gluteal muscle	UBERON:0002000	91.28	silver quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	91.28	gold quality
pons	UBERON:0000988	91.16	gold quality
lateral globus pallidus	UBERON:0002476	91.00	gold quality
diaphragm	UBERON:0001103	90.94	silver quality
inferior olivary complex	UBERON:0002127	90.79	gold quality
cervix squamous epithelium	UBERON:0006922	90.70	gold quality
pharyngeal mucosa	UBERON:0000355	90.68	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	90.59	gold quality
dorsal plus ventral thalamus	UBERON:0001897	90.48	gold quality
ventral tegmental area	UBERON:0002691	90.14	gold quality
medulla oblongata	UBERON:0001896	90.06	gold quality
inferior vagus X ganglion	UBERON:0005363	90.03	gold quality
superior surface of tongue	UBERON:0007371	89.72	gold quality
superior vestibular nucleus	UBERON:0007227	89.39	gold quality
substantia nigra pars compacta	UBERON:0001965	88.83	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.69

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA3, TBX21

miRNA regulators (miRDB)

9 targeting FUT7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-1225-3P	97.29	64.60	876
HSA-MIR-6849-3P	97.25	64.57	1371
HSA-MIR-1306-5P	97.11	64.04	755
HSA-MIR-1233-3P	96.81	65.44	573
HSA-MIR-6781-5P	94.61	59.49	155

Literature-anchored findings (GeneRIF, showing 22)

• The Fuc-T VII promoter is transactivated by Tax in concert with CBP through a CRE-like sequence in a manner similar to that of viral CRE in HTLV-1 LTR. (PMID:12506041)
• H-Ras mediates FucT-VII induction in Jurkat T cells via the activation of the Raf, PI3K, and a distinct, H-Ras-specific effector signaling pathway. (PMID:15262995)
• These results suggest that the FucT-VII may be a major regulator of the biosynthesis of the sLe(x)-epitopes on T lymphoblasts. (PMID:15464988)
• human FucT-IV and -VII both contribute and cooperate in regulating L-selectin-, P-selectin-, and E-selectin-dependent rolling on PSGL-1, with FucT-VII playing a predominant role in conferring selectin binding activity to PSGL-1 (PMID:15579466)
• A differential functional impact of N-glycosylation on C2GnT-1 and FucT-VII and disclose that a strongly reduced FucT-VII activity retains the ability to fucosylate PSGL-1 on the core2-based binding site(s) for the three selectins. (PMID:15926890)
• Alpha 1,3-fucosyltransferase-VII regulates the signaling molecules of the insulin receptor pathway (PMID:17229154)
• The up regulation of alpha1,3FucT-VII mRNA and cell surface SLe(x) (alpha1,3FucT-VII product) by UV and down regulation of them by ATRA was speculated to be one of the mechanisms that alpha1,3FucT-VII decreased and increased [susceptibility to] apoptosis. (PMID:17436081)
• Overexpression of fucosyltransferase VII (FUT7) promotes embryo adhesion and implantation. (PMID:18402946)
• This is the first time to report that alpha1,3FucT-VII can regulate the mRNA expression of integrin. (PMID:18452157)
• Overexpression of alpha1,3 FucT-VII promoted the expression of CD24 and SLe X and is associated with colorectal carcinoma metastases. (PMID:20428816)
• After transfection of JAR cells with fucosyltransferase VII, the expression of FUT7 and sLeX synthesis were increased, and the percent adhesion of trophoblast cells to RL95-2 cell monolayer was significantly increased. (PMID:21197561)
• This study presents the first example of a distinct regulatory mechanism involving transcriptional down-regulation of Fut7 by MAPCs that could modulate the trafficking behavior of T cells in vivo. (PMID:24176542)
• The DNA demethylation within the fut7 gene controls selectin ligand expression in humans, including the inducible topographic commitment of T cells for skin and inflamed sites. (PMID:27591321)
• FUT7 silencing causes inhibition of adhesion and migration of HepG2 hepatocellular carcinoma cells in vitro. (PMID:28585149)
• FUT7 overexpression significantly promoted monocyte-endothelial adhesion, while FUT7 knockdown obviously inhibited IL-1beta-induced monocyte-endothelial adhesion (PMID:29138114)
• Knockdown of FUT7 inhibits human hepatocarcinoma cell proliferation. (PMID:30226570)
• the findings in this study suggest that hypomethylated CpG sites, present in four regions of the FOXP3 locus, CAMTA1 and FUT7 gene regions, can potentially be used to distinguish subsets of CD4+ T lymphocytes in both sexes. (PMID:30455694)
• High FUT7 expression and CD15 are associated with lung and brain metastasis. (PMID:31104223)
• Integrated analysis reveals the participation of IL4I1, ITGB7, and FUT7 in reshaping the TNBC immune microenvironment by targeting glycolysis. (PMID:34134578)
• Activation of alpha7 nicotinic acetylcholine receptors attenuates monocyte-endothelial adhesion through FUT7 inhibition. (PMID:34973535)
• Novel blood-based FUT7 DNA methylation is associated with lung cancer: especially for lung squamous cell carcinoma. (PMID:36463240)
• Identification of FUT7 hypomethylation as the blood biomarker in the prediction of early-stage lung cancer. (PMID:36898609)

Cross-species orthologs

15 orthologs

Organism	Symbol	Gene ID
mus_musculus	Fut7	ENSMUSG00000036587
rattus_norvegicus	Fut7	ENSRNOG00000014156
drosophila_melanogaster	FucTD	FBGN0035217
caenorhabditis_elegans		WBGENE00001505
caenorhabditis_elegans		WBGENE00001507
caenorhabditis_elegans		WBGENE00004010
caenorhabditis_elegans		WBGENE00006402
caenorhabditis_elegans		WBGENE00007211
caenorhabditis_elegans		WBGENE00012922
caenorhabditis_elegans		WBGENE00016163
caenorhabditis_elegans		WBGENE00017343
caenorhabditis_elegans		WBGENE00043986
caenorhabditis_elegans		WBGENE00044383
caenorhabditis_elegans		WBGENE00194870
caenorhabditis_elegans		WBGENE00206359

Paralogs (7): FUT5 (ENSG00000130383), FUT6 (ENSG00000156413), FUT3 (ENSG00000171124), FUT9 (ENSG00000172461), FUT10 (ENSG00000172728), FUT4 (ENSG00000196371), FUT11 (ENSG00000196968)

Protein

Protein identifiers

Alpha-(1,3)-fucosyltransferase 7 — Q11130 (reviewed: Q11130)

Alternative names: Fucosyltransferase 7, Fucosyltransferase VII, Galactoside 3-L-fucosyltransferase, Selectin ligand synthase

All UniProt accessions (1): Q11130

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the transfer of L-fucose, from a guanosine diphosphate-beta-L-fucose, to the N-acetyl glucosamine (GlcNAc) of a distal alpha2,3 sialylated lactosamine unit of a glycoprotein or a glycolipid-linked sialopolylactosamines chain through an alpha-1,3 glycosidic linkage and participates in the final fucosylation step in the biosynthesis of the sialyl Lewis X (sLe(x)), a carbohydrate involved in cell and matrix adhesion during leukocyte trafficking and fertilization. In vitro, also synthesizes sialyl-dimeric-Lex structures, from VIM-2 structures and both di-fucosylated and trifucosylated structures from mono-fucosylated precursors. However does not catalyze alpha 1-3 fucosylation when an internal alpha 1-3 fucosylation is present in polylactosamine chain and the fucosylation rate of the internal GlcNAc residues is reduced once fucose has been added to the distal GlcNAc. Also catalyzes the transfer of a fucose from GDP-beta-fucose to the 6-sulfated a(2,3)sialylated substrate to produce 6-sulfo sLex mediating significant L-selectin-dependent cell adhesion. Through sialyl-Lewis(x) biosynthesis, can control SELE- and SELP-mediated cell adhesion with leukocytes and allows leukocytes tethering and rolling along the endothelial tissue thereby enabling the leukocytes to accumulate at a site of inflammation. May enhance embryo implantation through sialyl Lewis X (sLeX)-mediated adhesion of embryo cells to endometrium. May affect insulin signaling by up-regulating the phosphorylation and expression of some signaling molecules involved in the insulin-signaling pathway through SLe(x) which is present on the glycans of the INSRR alpha subunit.

Subcellular location. Golgi apparatus. Golgi stack membrane.

Tissue specificity. Leukocytic/myeloid lineage cells.

Post-translational modifications. N-glycosylated.

Activity regulation. Inhibited by NaCl. Inhibited by GDP in a concentration dependent manner, with an IC(50) value of 93 uM. Also inhibited by GMP and GTP. Inhibited by N-ethylmaleimide. Activated by poly(ethylene glycol) by enhancing the thermal stability of FUT7. Activated by Mn2+, Ca2+, and Mg2+. Both panosialin A and B inhibit activity with IC(50) values of 4.8 and 5.3 ug/ml, respectively. Inhibited by gallic acid (GA) and (-)-epigallocatechin gallate (EGCG) in a time-dependent and irreversible manner with IC(50) values of 60 and 700 nM, respectively.

Induction. By T-cell activation. Up-regulated by LIF. Induced by IL1B. Induced at higher levels by interleukin 12 in activated T cells. Down-regulated by IL4.

Pathway. Protein modification; protein glycosylation.

Similarity. Belongs to the glycosyltransferase 10 family.

RefSeq proteins (1): NP_004470* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001503	Glyco_trans_10	Family
IPR031481	Glyco_tran_10_N	Domain
IPR038577	GT10-like_C_sf	Homologous_superfamily
IPR055270	Glyco_tran_10_C	Domain

Pfam: PF00852, PF17039

Enzyme classification (BRENDA):

• EC 2.4.1.152 — 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase (BRENDA: 24 organisms, 171 substrates, 55 inhibitors, 103 Km, 24 kcat entries)
• EC 2.4.1.214 — glycoprotein 3-alpha-L-fucosyltransferase (BRENDA: 15 organisms, 84 substrates, 46 inhibitors, 60 Km, 0 kcat entries)
• EC 2.4.1.65 — 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase (BRENDA: 16 organisms, 191 substrates, 64 inhibitors, 119 Km, 15 kcat entries)

Substrate kinetics (BRENDA)

125 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GDP-FUCOSE	0.03–0.244	19
GDP-BETA-L-FUCOSE	0.0001–1.12	18
GDP-FUCOSE	0.065–0.8	14
N-ACETYLLACTOSAMINE	0.0026–0.61	9
GDP-L-FUCOSE	0.005–0.035	8
LACNAC	0.7–8.92	7
D-LACTOSE	72–543	6
N-ACETYLLACTOSAMINE	0.71–12.77	6
GAL-BETA-1,4-GLCNAC-O-(CH2)8CO2CH3	0.17–2.2	6
GDP-FUCOSE	0.0016–0.06	5
GDP-L-FUCOSE	0.0055–0.062	5
GDP-BETA-L-FUCOSE	0.1–1	5
GDP-L-FUCOSE	0.019–0.336	5
FUCALPHA(1,2)GALBETA(1,3)GLCNAC	0.1–3.8	5
FUCALPHA(1,2)GALBETA(1,4)GLCNAC	0.7–3.9	4

Catalyzed reactions (Rhea), 8 shown:

• a neolactoside VI(3)-alpha-NeuNAc-nLc6Cer + GDP-beta-L-fucose = a neolactoside VI(3)-alpha-NeuAc,V(3)-alphaFuc-nLc6Cer + GDP + H(+) (RHEA:48356)
• a neolactoside IV(3)-alpha-NeuAc-nLc4Cer + GDP-beta-L-fucose = a neolactoside IV(3)-alpha-NeuNAc,III(3)-alpha-Fuc-nLc4Cer + GDP + H(+) (RHEA:48392)
• an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc derivative + GDP-beta-L-fucose = an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc derivative + GDP + H(+) (RHEA:52864)
• an N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + GDP-beta-L-fucose = an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc derivative + GDP + H(+) (RHEA:56076)
• an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc6S derivative + GDP-beta-L-fucose = an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc6S derivative + GDP + H(+) (RHEA:62004)
• alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc + GDP-beta-L-fucose = alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc + GDP + H(+) (RHEA:62008)
• alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc + GDP-beta-L-fucose = alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc + GDP + H(+) (RHEA:62056)
• alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc + GDP-beta-L-fucose = alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc + GDP + H(+) (RHEA:62060)

UniProt features (14 total): disulfide bond 3, topological domain 2, mutagenesis site 2, sequence conflict 2, glycosylation site 2, chain 1, transmembrane region 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q11130-F1	92.90	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 68–76, 211–214, 318–321

Glycosylation sites (2): 81, 291

Mutagenesis-validated functional residues (2):

Position	Phenotype
81	impairs glycosylation. impairs glycosylation; when associated with q-291. does not affect selp and sell binding on selpl
291	slightly affects glycosylation. impairs glycosylation; when associated with q-81. does not affect selp and sell binding

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9037629	Lewis blood group biosynthesis

MSigDB gene sets: 244 (showing top): CREL_01, GOBP_OLIGOSACCHARIDE_METABOLIC_PROCESS, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_REGULATION_OF_INFLAMMATORY_RESPONSE_TO_ANTIGENIC_STIMULUS, GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_INFLAMMATORY_RESPONSE, GOBP_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, MODULE_45, GOBP_ALPHA_BETA_T_CELL_DIFFERENTIATION, GOBP_MONOSACCHARIDE_CATABOLIC_PROCESS, MODULE_16, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_REGULATION_OF_LEUKOCYTE_MIGRATION, GOBP_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS

GO Biological Process (28): regulation of type IV hypersensitivity (GO:0001807), CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation (GO:0002361), leukocyte migration involved in immune response (GO:0002522), leukocyte migration involved in inflammatory response (GO:0002523), ceramide metabolic process (GO:0006672), inflammatory response (GO:0006954), embryo implantation (GO:0007566), glycoprotein biosynthetic process (GO:0009101), oligosaccharide biosynthetic process (GO:0009312), regulation of cell-cell adhesion (GO:0022407), positive regulation of cell-cell adhesion (GO:0022409), L-fucose catabolic process (GO:0042355), positive regulation of cell adhesion (GO:0045785), regulation of insulin receptor signaling pathway (GO:0046626), regulation of cell adhesion molecule production (GO:0060353), T cell migration (GO:0072678), lymphocyte migration into lymph node (GO:0097022), positive regulation of neutrophil migration (GO:1902624), regulation of leukocyte cell-cell adhesion (GO:1903037), regulation of leukocyte tethering or rolling (GO:1903236), positive regulation of leukocyte tethering or rolling (GO:1903238), positive regulation of leukocyte adhesion to vascular endothelial cell (GO:1904996), regulation of neutrophil extravasation (GO:2000389), obsolete protein glycosylation (GO:0006486), sphingolipid metabolic process (GO:0006665), obsolete fucosylation (GO:0036065), lymphocyte migration into lymphoid organs (GO:0097021), regulation of leukocyte adhesion to vascular endothelial cell (GO:1904994)

GO Molecular Function (6): fucosyltransferase activity (GO:0008417), 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity (GO:0017083), alpha-(1->3)-fucosyltransferase activity (GO:0046920), protein binding (GO:0005515), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757)

GO Cellular Component (5): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), trans-Golgi network (GO:0005802), membrane (GO:0016020), Golgi cisterna membrane (GO:0032580)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Blood group systems biosynthesis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
leukocyte migration	2
regulation of cell adhesion	2
cell-cell adhesion	2
regulation of cell-cell adhesion	2
type IV hypersensitivity	1
regulation of T cell mediated immunity	1
regulation of hypersensitivity	1
CD4-positive, alpha-beta T cell differentiation	1
regulatory T cell differentiation	1
immune effector process	1
immune response	1
inflammatory response	1
sphingolipid metabolic process	1
defense response	1
multicellular organism development	1
female pregnancy	1
reproductive process	1
macromolecule biosynthetic process	1
glycoprotein metabolic process	1
carbohydrate derivative biosynthetic process	1
oligosaccharide metabolic process	1
carbohydrate biosynthetic process	1
positive regulation of cell adhesion	1
hexose catabolic process	1
L-fucose metabolic process	1
cell adhesion	1
positive regulation of cellular process	1
insulin receptor signaling pathway	1
regulation of signal transduction	1
regulation of cellular process	1
cell adhesion molecule production	1
lymphocyte migration	1
lymphocyte migration into lymphoid organs	1
positive regulation of leukocyte migration	1
regulation of neutrophil migration	1
neutrophil migration	1
leukocyte cell-cell adhesion	1
regulation of cellular extravasation	1
leukocyte tethering or rolling	1
regulation of leukocyte adhesion to vascular endothelial cell	1

Protein interactions and networks

STRING

802 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FUT7	SELP	P16109	886
FUT7	SELE	P16111	868
FUT7	HECA	Q9UBI9	820
FUT7	SELPLG	Q14242	787
FUT7	ZBTB32	Q9Y2Y4	727
FUT7	GCNT1	Q02742	714
FUT7	FUT1	P19526	702
FUT7	FUT8	Q9BYC5	685
FUT7	ST3GAL4	Q11206	683
FUT7	CHST4	Q8NCG5	678
FUT7	SNX20	Q7Z614	656
FUT7	SELL	P14151	648
FUT7	ST3GAL6	Q9Y274	626
FUT7	ST3GAL1	Q11201	599
FUT7	ST3GAL3	Q11203	592

IntAct

9 interactions, top by confidence:

A	B	Type	Score
FUT7	CTXN3	psi-mi:“MI:0915”(physical association)	0.560
CXCL9	FUT7	psi-mi:“MI:0915”(physical association)	0.560
FUT7	HSPA5	psi-mi:“MI:0914”(association)	0.350
GPR160	FUT7	psi-mi:“MI:0914”(association)	0.350
CTXN3	FUT7	psi-mi:“MI:0915”(physical association)	0.000
CXCL9	FUT7	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (6): FUT7 (Two-hybrid), CTXN3 (Two-hybrid), FUT7 (Affinity Capture-MS), YTHDF1 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), FUT7 (Negative Genetic)

ESM2 similar proteins: A1A4L8, A1A4Q9, A1L134, A2BDX3, A5YM72, A6H707, B0BLZ5, B0JZP3, G3MZR2, O43292, O60831, O89109, P70295, Q11130, Q2TBP5, Q2V8X7, Q32NY4, Q3UPE3, Q4R4E4, Q4R4I9, Q5XIE1, Q5ZIW1, Q66HR0, Q6IQX7, Q6NRK8, Q6P2H8, Q7L1V2, Q80ZW2, Q86VU5, Q8IZ52, Q8N3Y3, Q8NE01, Q8NF37, Q8NI29, Q8TAC2, Q8TCD5, Q8TD43, Q8WUY1, Q92839, Q96DE0

Diamond homologs: G3MZR2, G5EDR5, O19058, O88819, P21217, P22083, P51993, P56433, P56434, P83088, Q11126, Q11127, Q11128, Q11130, Q11131, Q62994, Q659K9, Q659L0, Q659L1, Q712G6, Q8HYJ3, Q8HYJ4, Q8HYJ5, Q8HYJ6, Q8HYJ7, Q8HZR2, Q8HZR3, Q99JB3, Q9FX97, Q9GKU6, Q9JIG1, Q9LJK1, Q9VUL9, Q9Y231, G5EE06, G5EEE1, G5EFP5, O30511, Q495W5, Q70AG8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	52
Likely benign	7
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

398 predictions. Top by Δscore:

Variant	Effect	Δscore
9:137032714:C:A	donor_gain	0.9800
9:137032713:T:TA	donor_gain	0.9700
9:137031578:CAG:C	acceptor_gain	0.9600
9:137032693:T:TA	donor_gain	0.9600
9:137031579:A:T	acceptor_gain	0.9400
9:137031724:CCCTG:C	acceptor_loss	0.9400
9:137031725:CCTGC:C	acceptor_loss	0.9400
9:137031726:CTGCA:C	acceptor_loss	0.9400
9:137031727:T:G	acceptor_loss	0.9400
9:137032644:TCTGC:T	donor_gain	0.9400
9:137032645:CTGCC:C	donor_gain	0.9400
9:137032648:C:CT	donor_gain	0.9400
9:137031724:CC:C	acceptor_gain	0.9300
9:137031725:CC:C	acceptor_gain	0.9300
9:137031584:C:CT	acceptor_gain	0.9200
9:137032014:A:T	acceptor_gain	0.9200
9:137032734:G:A	donor_gain	0.9200
9:137031723:GCCCT:G	acceptor_loss	0.9000
9:137031724:CCCT:C	acceptor_loss	0.9000
9:137031725:CCTG:C	acceptor_loss	0.9000
9:137031726:CTGC:C	acceptor_loss	0.9000
9:137031727:T:C	acceptor_loss	0.9000
9:137032706:A:AC	donor_gain	0.9000
9:137031568:A:T	acceptor_gain	0.8900
9:137031577:CCAG:C	acceptor_gain	0.8900
9:137031580:G:C	acceptor_gain	0.8900
9:137031733:A:T	acceptor_gain	0.8900
9:137031978:CCAG:C	donor_gain	0.8900
9:137032783:T:TA	donor_gain	0.8900
9:137032646:TGC:T	donor_gain	0.8800

AlphaMissense

2183 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:137031313:G:C	S142R	0.994
9:137031313:G:T	S142R	0.994
9:137031315:T:G	S142R	0.994
9:137030926:G:C	F271L	0.988
9:137030926:G:T	F271L	0.988
9:137030928:A:G	F271L	0.988
9:137031023:T:A	E239V	0.988
9:137031049:G:C	N230K	0.988
9:137031049:G:T	N230K	0.988
9:137031020:T:A	K240I	0.987
9:137031053:T:A	E229V	0.987
9:137031067:G:C	F224L	0.987
9:137031067:G:T	F224L	0.987
9:137031069:A:G	F224L	0.987
9:137031464:A:T	V92D	0.983
9:137031387:A:G	W118R	0.982
9:137031387:A:T	W118R	0.982
9:137031059:G:T	S227Y	0.980
9:137031068:A:G	F224S	0.979
9:137031328:G:C	F137L	0.979
9:137031328:G:T	F137L	0.979
9:137031330:A:G	F137L	0.979
9:137030908:A:C	F277L	0.977
9:137030908:A:T	F277L	0.977
9:137030910:A:G	F277L	0.977
9:137031013:C:A	W242C	0.977
9:137031013:C:G	W242C	0.977
9:137031015:A:G	W242R	0.976
9:137031015:A:T	W242R	0.976
9:137030777:C:T	C321Y	0.975

dbSNP variants (sampled 300 via entrez): RS1000227654 (9:137032851 T>C), RS1000324 (9:137033913 G>A), RS1000940518 (9:137030164 A>G), RS1001032959 (9:137033121 G>A), RS1002308186 (9:137032670 C>G), RS1003063309 (9:137031516 G>A,C), RS1004303319 (9:137031245 G>A,T), RS1005502796 (9:137030498 C>T), RS1005928553 (9:137033950 T>C), RS1006391823 (9:137030483 G>A,C), RS1006593295 (9:137032808 C>A), RS1006617775 (9:137030184 A>G), RS1007598233 (9:137033948 G>A,T), RS1007712352 (9:137033653 G>A,T), RS1008291424 (9:137031802 C>A,T)

Disease associations

OMIM: gene MIM:602030 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST004627_4	Lymphocyte count	1.000000e-13
GCST90002388_231	Lymphocyte count	4.000000e-21
GCST90002389_358	Lymphocyte percentage of white cells	2.000000e-11

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004587	lymphocyte count
EFO:0007993	lymphocyte percentage of leukocytes

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3596077 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 103,233 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL288114	GALLIC ACID	2	103,233

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

3 measured of 7 human assays (11 total across all organisms); most potent 3 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Gallic Acid, F	IC50	14000 nM
Guanosine Diphosphate	IC50	24000 nM
2,5-Dihydroxybenzoate, VI	IC50	115000 nM

ChEMBL bioactivities

5 potent at pChembl≥5 of 5 total, top 5 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.22	IC50	60	nM	GALLIC ACID
6.16	IC50	700	nM	CHEMBL338988
5.37	IC50	4300	nM	CHEMBL3596265
5.32	IC50	4800	nM	CHEMBL3596264
5.10	IC50	8000	nM	GALLIC ACID METHYL ESTER

PubChem BioAssay actives

6 with measured affinity, of 14 total; 4 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
Gallic Acid	1799773: SPA Assay from Article 10.1016/j.abb.2004.02.039: “Inhibition of fucosyltransferase VII by gallic acid and its derivatives.”	ic50	0.0600	uM
[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate	1799773: SPA Assay from Article 10.1016/j.abb.2004.02.039: “Inhibition of fucosyltransferase VII by gallic acid and its derivatives.”	ic50	0.7000	uM
[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate	1799773: SPA Assay from Article 10.1016/j.abb.2004.02.039: “Inhibition of fucosyltransferase VII by gallic acid and its derivatives.”	ic50	2.3000	uM
methyl 3,4,5-trihydroxybenzoate	1799773: SPA Assay from Article 10.1016/j.abb.2004.02.039: “Inhibition of fucosyltransferase VII by gallic acid and its derivatives.”	ic50	8.0000	uM

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects expression, increases abundance, increases expression	2
Particulate Matter	increases abundance, increases expression	2
GSK-J4	decreases expression	1
fluorene-9-bisphenol	decreases expression	1
aminomethylphosphonic acid (AMPA)	increases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	affects expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression, affects response to substance, increases expression, affects cotreatment	1
Am 580	decreases expression	1
Rosiglitazone	decreases expression	1
Arsenic Trioxide	increases expression	1
Lipopolysaccharides	affects response to substance, increases expression, affects cotreatment, decreases expression	1
Ozone	affects expression, increases abundance	1
Pantothenic Acid	decreases expression	1
Valproic Acid	increases methylation	1
2,4-Dichlorophenoxyacetic Acid	increases expression	1
Sodium Selenite	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3598450	Binding	Inhibition of FucT-7 (unknown origin)	Beyond substrate analogues: new inhibitor chemotypes for glycosyltransferases — Medchemcomm

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.